|  |  |
| --- | --- |
| Trial Name: |  |
| Trial Description:(short summary re purpose of trial) |  |
| Study Registration Number: |  |
| Ethics Approval ID: |  |
| Ethics Approving Body: |  |
| Expected start date: |  |
| Expected end date: |  |
| Trial time zone: |  |
| Number of system users: |  |

|  |  |
| --- | --- |
| Sample size: |  |
| Type of study: (tick one) | [ ] Parallel [ ]  Cluster [ ] Crossover [ ] Factorial |
| Randomisation method: (tick one) | [ ] Blocked [ ] Urn [ ] Minimisation [ ] Standard  |
| Stratify by participant: (Provide heading/s and options) |  |
| Stratify by sites: (tick one) | [ ] Yes [ ] No |
| Block size – minimum: (if applicable)Block size must be divisible by the number of study groups. \* |  |
| Block size – maximum: (if applicable) |  |
| Participant Identity Hint: (optional)To identify the participant if required | [ ] Yes [ ] No |
| Participant ID Hint label: (optional)What you would like to use for the identity hint |  |
| Participant ID duplication: (tick one)System response to duplication  | [ ] Ignore [ ] Warn [ ] Block |
| Exclude flagged participants: (from count) | [ ] Yes [ ] No |
| Study Group Names: (please list) |  |
| Site Names: (please list) |  |

\* A small number here increases the likelihood of repetitive allocation patterns. E.g. a minimum block size of 2 increases the probability that allocations may group A, B, A, B for long ‘runs’

|  |  |
| --- | --- |
| Organisation Name: |  |
| Trial Contact Name: |  |
| Trial Chief Investigator: |  |
| Billing Address: |  |